Advance the clinical development of oxfendazole as an anti-parasitic macrofilaricidal treatment
current phase of drug development
updated 1 Jun 2021
Screening of drug libraries obtained from biotech and pharmaceutical companies, along with active screening of the literature, identified oxfendazole, a veterinary product used for deworming in animals, as a potential macrofilaricidal treatment for river blindness.
Based on highly encouraging pre-clinical data on the efficacy of oxfendazole, DNDi is evaluating the use of oxfendazole for filarial infections. DNDi is moving ahead with pharmaceutical development of the drug, and the HELP Consortium, of which DNDi is a member, will conduct a Phase I clinical trial.
HELP Consortium: an international network to speed up identification of new treatments for worm-related diseases
Launched in 2019, the Helminth Elimination Platform (HELP) led by the Swiss Tropical and Public Health Institute (Swiss TPH) convenes key players in research and development for filarial diseases. The multidisciplinary consortium works to identify new treatments against nematode worms, including onchocerciasis, lymphatic filariasis, hookworm, and whipworm. The HELP consortium is comprised of the Swiss TPH and DNDi in Switzerland; the Institute for Medical Microbiology, Immunology and Parasitology at the Universitätsklinikum Bonn in Germany; the Muséum National d’Histoire Naturelle in France; the Ifakara Health Institute in Tanzania; the University of Buea in Cameroon; and Bristol-Myers Squibb and Elanco Animal Health in the United States.
- Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro. PLOS Neglected Tropical Diseases, July 2020.
Get our latest news, personal stories, research articles, and job opportunities.